Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Flourishing in a Remote Workplace: Individual Techniques - 2Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship
- 3Who is behind Al-Majd, the Israeli-linked evacuation group sending Gazans to South Africa?
- 4Only 30% of young people in Israel optimistic about future, Aluma survey reveals
- 5Shrapnel hits across central Israel, injuring several, causing property damage
- Vote in favor of your #1 Kind of Cap
- Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- Two UN peacekeepers killed in explosion in Lebanon
- Iran Used $2 Billion in Crypto to Run Its Militant Proxies in 2025
- Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- 10 Work Valuable chances to Assist with supporting Your Advanced degree
- Vote In favor of Your Favored Pizza Cover
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application
